ArticlePharmacoEconomics - open2025

Correction: Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy.

Jonathan Salcedo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.